Ye Li

12PUBLICATIONS
85CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapyReaction engineering (excl. nuclear reactions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur

|Jun 04, 2025
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells.

Hind Rafei, Rafet Basar, Sunil Acharya

|Apr 04, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur

|Sep 11, 2024
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.

Bijender Kumar, Anand Singh, Rafet Basar

|Jun 20, 2024
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis.

Sunil Acharya, Rafet Basar, May Daher

|Jan 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trial.

David Marin, Ye Li, Rafet Basar

Pageof 2

Frequent Collaborators

11 joint publications

Katayoun Rezvani

8 joint publications

Hind Rafei

7 joint publications

Ken Chen

7 joint publications

May Daher